ABBV - AbbVie Inc Stock Price, Fair Value and News

$175.62+4.10 (+2.39%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ABBV Price Action

Last 7 days

1.3%

Last 30 days

4.7%

Last 90 days

-9.2%

Trailing 12 Months

15.1%

ABBV RSI Chart

ABBV Valuation

Market Cap

310.3B

Price/Earnings (Trailing)

60.59

Price/Sales (Trailing)

5.59

EV/EBITDA

45.53

Price/Free Cashflow

19.86

ABBV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ABBV Fundamentals

ABBV Revenue

Revenue (TTM)

55.5B

Rev. Growth (Yr)

3.83%

Rev. Growth (Qtr)

-0.01%

ABBV Earnings

Earnings (TTM)

5.1B

Earnings Growth (Yr)

-12.2%

Earnings Growth (Qtr)

13.94%

ABBV Profitability

EBT Margin

12.96%

Return on Equity

84.91%

Return on Assets

3.57%

Free Cashflow Yield

5.03%

ABBV Investor Care

Dividend Yield

1.31%

Dividend/Share (TTM)

2.63

Shares Dilution (1Y)

0.09%

Diluted EPS (TTM)

2.88

ABBV Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	54.4B	55.0B	55.5B	0
2023	56.7B	56.0B	55.1B	54.3B
2022	56.7B	57.3B	57.8B	58.1B
2021	50.2B	53.7B	55.2B	56.2B
2020	34.1B	36.2B	40.6B	45.8B
2019	32.6B	32.6B	32.9B	33.3B
2018	29.6B	30.9B	32.2B	32.8B
2017	26.2B	26.7B	27.3B	28.2B
2016	23.8B	24.8B	25.2B	25.6B
2015	20.4B	21.0B	21.9B	22.9B
2014	19.0B	19.3B	19.6B	20.0B
2013	18.5B	18.7B	18.9B	18.8B
2012	17.7B	17.9B	18.1B	18.4B
2011	0	0	0	17.4B
2010	0	0	0	15.6B

Get all data in R, Python etc through our Historical Stock Data APIs

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal BehÃƒÆ’Ã‚Â§et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

CEO	Mr. Richard A. Gonzalez
WEBSITE	abbvie.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers General
EMPLOYEES	50000

AbbVie Inc Frequently Asked Questions

What is the ticker symbol for AbbVie Inc? What does ABBV stand for in stocks?

ABBV is the stock ticker symbol of AbbVie Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbbVie Inc (ABBV)?

As of Fri Dec 20 2024, market cap of AbbVie Inc is 310.35 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart for subscribers.

Is AbbVie Inc a good stock to buy?

The fair value guage provides a quick view whether ABBV is over valued or under valued. Whether AbbVie Inc is cheap or expensive depends on the assumptions which impact AbbVie Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABBV.

What is AbbVie Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ABBV's PE ratio (Price to Earnings) is 60.59 and Price to Sales (PS) ratio is 5.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABBV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AbbVie Inc's stock?

In the past 10 years, AbbVie Inc has provided 0.106 (multiply by 100 for percentage) rate of return.